STOCK TITAN

Evommune (EVMN) grants 115,279 stock options to chief legal officer

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Evommune, Inc. reported that Chief Business & Legal Officer Gregory S. Moss received an option grant for 115,279 shares of common stock at an exercise price of $26.77 per share. The options expire on April 15, 2036 and represent his entire reported option position from this grant.

According to the vesting terms, one fourth of the shares will vest on the first anniversary of the grant date, and the remaining shares will vest in 36 equal monthly installments thereafter, subject to his continuous service with the company.

Positive

  • None.

Negative

  • None.
Insider Moss Gregory S.
Role Chief Business & Legal Officer
Type Security Shares Price Value
Grant/Award Employee Stock Option (Right to Buy) 115,279 $0.00 --
Holdings After Transaction: Employee Stock Option (Right to Buy) — 115,279 shares (Direct)
Footnotes (1)
  1. [object Object]
Option Grant Size 115,279 shares Employee stock option grant to Chief Business & Legal Officer
Exercise Price $26.77 per share Stock option exercise price for the 115,279-share grant
Total Options After Grant 115,279 options Total derivative securities held following the reported transaction
Expiration Date April 15, 2036 Option expiration for the 115,279-share grant
Initial Vesting Portion 25% of shares One fourth vests on the first anniversary of the grant date
Remaining Vesting Schedule 36 monthly installments Remainder vests in 36 equal monthly installments after first anniversary
Employee Stock Option financial
"security_title: "Employee Stock Option (Right to Buy)""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
exercise price financial
"conversion_or_exercise_price: "26.7700""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
grant date financial
"shares subject to the option award shall vest on the first anniversary of the grant date"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
vesting financial
"shares subject to the option shall vest in thirty-six (36) equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Moss Gregory S.

(Last)(First)(Middle)
C/O EVOMMUNE, INC.
1891 PAGE MILL ROAD

(Street)
PALO ALTO CALIFORNIA 94304

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Business & Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy)$26.7704/16/2026A115,279 (1)04/15/2036Common Stock115,279$0.00115,279D
Explanation of Responses:
1. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Remarks:
/s/ Gregory S. Moss04/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Evommune (EVMN) disclose in this Form 4?

Evommune disclosed that Chief Business & Legal Officer Gregory S. Moss received an employee stock option grant for 115,279 shares. These options allow him to buy Evommune common stock at a fixed price in the future, subject to vesting conditions and an expiration date.

How many Evommune (EVMN) shares are covered by Gregory Moss’s new options?

The option grant covers 115,279 shares of Evommune common stock. This is the number of shares he can purchase under the award if the options vest and are exercised before expiration, according to the terms described in the filing and related footnote.

What is the exercise price of Gregory Moss’s Evommune (EVMN) stock options?

The options have an exercise price of $26.77 per share. This means Moss can buy Evommune common stock at $26.77 for each optioned share once they vest and before they expire, regardless of the market price at that time.

When do Gregory Moss’s Evommune (EVMN) stock options vest?

One fourth of the option shares vest on the first anniversary of the grant date. The remaining shares then vest in 36 equal monthly installments, as long as Moss maintains continuous service with Evommune through each applicable vesting date.

When do Gregory Moss’s Evommune (EVMN) stock options expire?

The options expire on April 15, 2036. After that date, any unexercised options will no longer be exercisable, so Moss must exercise any vested options he wishes to use before the stated expiration date in the grant terms.

Is Gregory Moss’s Evommune (EVMN) option grant an open-market stock purchase?

No, this is a compensation-related stock option grant, not an open-market share purchase. The options were awarded at no cost per option and give Moss the right to buy shares later at $26.77, subject to vesting and expiration conditions.